Assignee
KALOBIOS PHARMACEUTICALS INC
US·6 granted patents·15 pending applications·52 citations·filing 2002–2016
Top patents by PatentIndex Score
21 records- 0193US7981843B2Antibody specificity transfer using minimal essential binding determinantsKALOBIOS PHARMACEUTICALS INC·Filed 2005·Granted Jul 19, 2011·36 cites·14 claims
- 0270US7432063B2Methods for affinity maturationKALOBIOS PHARMACEUTICALS INC·Filed 2003·Granted Oct 7, 2008·11 cites·26 claims
- 0367US2015030614A1Antibodies to the pcrv antigen of pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0465US8044181B2Antibodies to the PcrV antigen of Pseudomonas aeruginosaKALOBIOS PHARMACEUTICALS INC·Filed 2008·Granted Oct 25, 2011·0 cites·15 claims
- 0562US7335478B2Reactivation-based molecular interaction sensorsKALOBIOS PHARMACEUTICALS INC·Filed 2002·Granted Feb 26, 2008·5 cites·29 claims
- 0660US2014370010A1Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3KALOBIOS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0759US2009181020A1Methods of Treating Bone-Loss Disorders Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 0856US9290571B2Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2013·Granted Mar 22, 2016·0 cites·20 claims
- 0956US2008206241A1Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF AntagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1054US8354251B2Transactivation system for mammalian cellsKALOBIOS PHARMACEUTICALS INC·Filed 2004·Granted Jan 15, 2013·0 cites·2 claims
- 1154US2017226227A1Treatment of Leukemias and Chronic Myeloproliferative Diseases with Antibodies to EphA3KALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1251US2013156759A1Methods of treating dementia using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1351US2015329647A1Methods of Treating Hematological Proliferative Disorders by Targeting EphA3 Expressed on Aberrant Vasculature in Bone MarrowKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1449US2008171038A1Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1546US2015344565A1Antibodies to granulocyte-macrophage colony-stimulating factorKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1644US2017335001A1Detection of EphA3 as a Marker of the Presence of a Solid TumorKALOBIOS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1743US2013109586A1Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acidKALOBIOS PHARMACEUTICALS INC·Filed 2012·Application pending·0 cites
- 1842US2011245100A1Generation of antibodies to an epitope of interestKALOBIOS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 1942US2015246121A1Methods of treating chronic inflammatory diseases using a gm-csf antagonistKALOBIOS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2037US2011243934A1Epha3 antibodies for the treatment of multiple myelomaKALOBIOS PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 2133US2010272736A1Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infectionKALOBIOS PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KALOBIOS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →